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Mycobacterium tuberculosis (M. tuberculosis) infections are uncommon in recipients of
hematopoietic stem cell transplantation. These infections are 10–40 times commoner in
recipients of stem cell transplantation than in the general population but they are 10 times
less in stem cell transplantation recipients compared to solid organ transplant recipients.
The incidence of M. tuberculosis infections in recipients of allogeneic stem cell trans-
plantation ranges between <1 and 16% and varies considerably according to the type
of transplant and the geographical location. Approximately 80% of M. tuberculosis infec-
tions in stem cell transplant recipients have been reported in patients receiving allografts.
Several risk factors predispose to M. tuberculosis infections in recipients of hematopoi-
etic stem cell transplantation and these are related to the underlying medical condition
and its treatment, the pre-transplant conditioning therapies in addition to the transplant
procedure and its own complications. These infections can develop as early as day 11
and as late as day 3337 post-transplant. The course may become rapidly progressive and
the patient may develop life-threatening complications. The diagnosis of M. tuberculosis
infections in stem cell transplant recipients is usually made on clinical grounds, cultures
obtained from clinical specimens, tissues biopsies in addition to serology and molecular
tests. Unfortunately, a definitive diagnosis of M. tuberculosis infections in these patients
may occasionally be difficult to be established. However,M. tuberculosis infections in trans-
plant recipients usually respond well to treatment with anti-tuberculosis agents provided
the diagnosis is made early. A high index of suspicion should be maintained in recipients
of stem cell transplantation living in endemic areas and presenting with compatible clinical
and radiological manifestations. High mortality rates are associated with infections caused
by multidrug-resistant strains, miliary or disseminated infections, and delayed initiation of
therapy. In recipients of hematopoietic stem cell transplantation, isoniazid prophylaxis has
specific indications and bacillus Calmette-Guerin vaccination is contraindicated as it may
lead to disseminated infection. The finding that M. tuberculosis may maintain long-term
intracellular viability in human bone marrow-derived mesenchymal stem cells complicates
the development of effective vaccines and strategies to eliminate tuberculosis. However,
the introduction of linezolid, cellular immunotherapy, and immunomodulation in addition to
autologous mesenchymal stem cell transplantation will ultimately have a positive impact
on the overall management of infections caused by M. tuberculosis.
Keywords: Mycobacterium tuberculosis, hematological malignancy, latency, hematopoietic stem cell
transplantation, drug resistance
INTRODUCTION
Mycobacterium tuberculosis (M. tuberculosis) is an aerobic, acid
fast, non-spore forming non-motile bacillus that belongs to the
family Tuberculosisceae (1, 2). M. tuberculosis is pathogenic for
humans while Mycobacterium bovis is usually an animal pathogen
(1, 2). Tuberculosis (TB) is caused by members of M. tuberculosis
complex that include: M. tuberculosis, M. bovis, M. bovis BCG, M.
africanum, M. microti, M. pinipedii, M. caprae, and M. mungi (1, 3).
Once infected, active TB disease develops in 10% of patients,
while the remaining individuals enter into latency phase that can
reactivate at a later time especially if the immunity of the indi-
vidual declines (1, 4). Active TB develops in approximately 59%
of patients and is predominantly pulmonary in nature. Extra-
pulmonary TB occurs in 41% of patients and the clinical man-
ifestations depend on the primary site of involvement. Latent
TB infection (LTBI) is not contagious, has no clinical manifes-
tations but can reactivate following reduction in immunity (1, 4,
5). Immunocompromised individuals including cancer patients,
transplant recipients, and those receiving immunosuppressive
therapies including monoclonal antibodies should be evaluated
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regularly and treated for LTBI at the time of diagnosis or just
before starting immunosuppressive treatment (1, 6).
M. TUBERCULOSIS INFECTIONS IN GENERAL
Several risk factors predispose individuals to M. tuberculosis infec-
tions in the general population and these are included in Table 1
(1, 2, 5, 7). Patients with hematologic malignancies (HM) are at
risk of developing M. tuberculosis infections. Specific predisposing
factors for M. tuberculosis infections in this group of patients are
shown in Table 2 (1, 5, 7).
THE GLOBAL SCENE OFM. TUBERCULOSIS INFECTIONS
Approximately eight million new cases of TB infection are reported
annually with the vast majority occurring in developing countries
and most of the new cases arise as reactivations of old TB infec-
tions. Out of these eight million cases, five million patients receive
some treatment and only half a million patients receive short
Table 1 | Risk factors forM. tuberculosis infections in the general
population.
(1) Human immunodeficiency virus infection
(2) Diabetes mellitus
(3) Hematologic malignancy and solid tumors
(4) Solid organ and hematopoietic stem cell transplantation
(5) End-stage renal disease
(6) Chronic liver disease
(7) Collagen vascular and autoimmune disorders
(8) Chronic and industrial lung diseases such as silicosis
(9) Tobacco smoking
(10) Alcoholism
(11) Use of illicit drugs
(12) Climate and travel
(13) Malnutrition
(14) Pregnancy
(15) Old age
(16) Imprisonment
(17) Genetic predisposition to M. tuberculosis infection
(18) Recent exposure to a patient with contagious tuberculosis
M. tuberculosis, Mycobacterium tuberculosis.
Table 2 | Risk factors forM. tuberculosis infections in patients with
HM.
(1) The primary hematological disorder, particularly at the time of relapse
(2) Corticosteroid therapy
(3) Cytotoxic chemotherapy
(4) Radiotherapy
(5) Other immunosuppressive therapies:
- Monoclonal antibodies such as rituximab and alemtuzumab
- Tyrosine kinase inhibitors such as imatinib
(6) Old age
(7) Presence of other comorbid medical conditions such as diabetes
mellitus and malnutrition
M. tuberculosis, Mycobacterium tuberculosis; HM, hematologic malignancy.
courses of direct observed therapy. Recently, the global rates of TB
are rising in Asia, Africa, and Latin America where co-infection
with human immunodeficiency virus (HIV) is common (1, 8).
The world health organization (WHO) declared TB a global
health emergency in the year 1993. One third of the world popu-
lation has LTBI and 5–10% of latent forms become active at any
time. Also, approximately 95% of TB cases and 98% of deaths
related to TB infection occur in poor countries (1, 9). Another
problem, which makes management of M. tuberculosis infections
a difficult task, is the evolution of drug resistance. Resistance to
anti-TB chemotherapy can be attributed to: (1) failure to complete
the course of anti-TB treatment, (2) weak health-care infrastruc-
tures particularly in third world countries, (3) lack of diagnostic
techniques and drug susceptibility testing (DST), and (4) having
no new anti-TB drugs available since the 1960s till the turn of the
century (1, 9). In a survey performed by the WHO in the year 1997,
drug resistant TB was found in all 35 countries included in that
survey and in the last survey done in the year 2000, drug resistant
TB was documented in all 100 countries surveyed (1, 10).
M. TUBERCULOSIS INFECTIONS IN RECIPIENTS OF HSCT
Hematopoietic stem cell transplantation (HSCT) can be defined as
the transfer of HSCs from one individual to another (allogeneic)
or the return of previously harvested HSCs to the same individual
(autologous) after manipulation of the cells and/or the recipi-
ent (11). Despite the recent advances in managing HSCT patients
and the progress in supportive care, infection is still reported as
the primary cause of death in 8% of autologous HSCT patients
and 17–20% of allogeneic HSCT recipients (11). Recipients of
allogeneic HSCT have severely impaired cell-mediated immunity
as a consequence of: (1) pre-transplant conditioning therapies,
(2) immunosuppressive treatments given in the post-transplant
period,and (3) graft versus host disease (GVHD) and its treatment,
which further suppress the immunity in HSCT recipients. Severe
suppression of cellular immunity makes HSCT patients at risk
of viral, bacterial, fungal, and mycobacterial infections (12, 13).
Recipients of T-cell depleted allografts and those having GVHD
may have more extensive and prolonged T-cell immunodeficiency
and this consequently predisposes them to severe infections (14).
For example, in recipients of T-cell depleted allografts in the
United States of America (USA), active TB has been reported in
0.69% of patients and all the reported cases originally came from
areas that are endemic for TB (14). At least 25% of M. tuberculosis
infections in recipients of HSCT result from reactivation of LTBIs
(1, 15, 16).
RISK FACTORS FORM. TUBERCULOSIS INFECTIONS IN HSCT
RECIPIENTS
There are several risk factors for the development of M. tuberculo-
sis infections in recipients of HSCT and these are listed in Table 3
(1, 5, 13, 14, 17–27).
EPIDEMIOLOGY OFM. TUBERCULOSIS INFECTIONS IN RECIPIENTS OF
HSCT
Infections caused by M. tuberculosis are 10–40 times commoner
in recipients of HSCT than in the general population. The inci-
dence of M. tuberculosis infections in recipients of HSCT varies
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Table 3 | Risk factors forM. tuberculosis infections in recipients of
HSCT.
(1) The primary hematological disorder, particularly:
- Acute myeloid leukemia
- Chronic myeloid leukemia
- Myelodysplastic syndrome
(2) Certain conditioning therapies, particularly:
- Busulphan
- Cyclophosphamide
- Total body irradiation
(3) Corticosteroid therapy
(4) T-cell depletion in allografts
(5) Matched unrelated allogeneic HSCT
(6) Mismatched allografts
(7) Acute and chronic graft versus host disease
(8) Bronchiolitis obliterans
(9) History of M. tuberculosis infection
M. tuberculosis, Mycobacterium tuberculosis; HSCT, hematopoietic stem cell
transplantation.
considerably according to the type of HSCT and to the geographi-
cal location (1, 14, 21, 23, 26–30). The prevalence of M. tuberculosis
infections is higher in recipients of solid organ transplant (SOT)
than in HSCT presumably due to the longer immunosuppression
in SOT recipients (15, 28, 31, 32). Incidences of M. tuberculosis
infections in HSCT recipients have been reported to be as low
as 0.0014% in the USA and as high as 16% in Pakistan (33). In
countries, such as Spain and Turkey, the incidence M. tuberculosis
was 1.6% while in Taiwan and Hong Kong, it was 8.57%. The vast
majority of M. tuberculosis infections have been reported from
Asia and the incidence of TB in recipients of allogeneic HSCT is
directly proportional to the incidence of TB in the general popu-
lation (1, 14, 21, 23, 26–29). Approximately 95% of TB infections
in allogeneic HSCT patients have been reported from developing
countries, where HSCT is infrequently performed, while the inci-
dence of M. tuberculosis infections in allograft recipients is low
in developed countries where HSCT is often performed. Usually,
M. tuberculosis infections develop 45–365 days post-HSCT and
most of the cases reported occurred after 90 days of HSCT. Studies
have shown that the diagnosis of TB infections is usually made at a
median of 257.2 days after HSCT and the range varies from as early
as 21 days to as late as 1410 days post-HSCT (1, 19, 21, 22, 32, 33).
CLINICAL ASPECTS OFM. TUBERCULOSIS INFECTIONS IN HSCT
RECIPIENTS
In recipients of HSCT, the lung is the most commonly involved
organ and lung involvement has been reported in 50–100% of
allografts (1, 21, 33–36). Pulmonary tuberculous infections after
HSCT are 13.1-fold higher than in the general population. Also,
the incidence of pulmonary TB infections is higher in recipients of
allogeneic HSCT than in recipients of auto-grafts. Pulmonary TB
may coexist with invasive fungal infections such as mucormyco-
sis or aspergillosis in HSCT recipients (1, 21, 33–36). In these
patients, lung involvement by TB may resemble that of inva-
sive fungal pulmonary infections and patients may even present
with bacteremia caused by M. tuberculosis and a rapidly pro-
gressive illness. In such situations, the use of computed axial
tomography (CAT scans) and molecular techniques such as poly-
merase chain reaction (PCR) may accelerate the diagnosis in this
group of immunocompromised hosts (34). Pulmonary TB should
be considered in the differential diagnosis of lung infections in
HSCT recipients living in geographical locations that are endemic
for TB (37).
At least one third of M. tuberculosis infections in recipients
of HSCT are disseminated at presentation with predominant
extra-pulmonary involvement. Extra-pulmonary sites of infec-
tion include: liver, spleen, bone, bone marrow, brain, and spine
(1, 13, 16, 24, 32, 38, 39). Central nervous system involvement may
take the form of space occupying lesions in the brain. Abdominal
involvement may be in the form of acute abdomen due to abdom-
inal masses causing acute abdominal pain and intestinal obstruc-
tion (1, 13, 16, 24, 32, 38, 39). In recipients of allogeneic HSCT,
M. tuberculosis infections may present in an atypical manner such
as pyrexia of unknown origin, non-specific features particularly in
patients with extra-pulmonary involvement. Therefore, it is essen-
tial not only to have a high index of suspicion but also to apply
prompt and appropriate diagnostic tools as well (13, 40).
The approach to LTBIs in recipients of allogeneic HSCT varies
considerably from one transplant center to another (14). The diag-
nosis of LTBI is also difficult in immunocompromised individuals
as they are likely to have attenuated response to tuberculin skin test
(TST). To prevent reactivation of LTBI in recipients of allogeneic
HSCT, it is recommended to consider administration of isoniazid
(INH) prior to and post-HSCT particularly in patients living in
areas that are endemic for TB (14).
M. TUBERCULOSIS INFECTIONS IN RECIPIENTS OF CERTAIN TYPES OF
HSCT
M. tuberculosis infections have been reported in various forms of
HSCT (5, 16, 19, 26, 29, 32, 41–44). The exact incidence of M.
tuberculosis infections among recipients of umbilical cord blood
transplant (UCBT) is unknown (16, 26, 41). The interval between
UCBT and the diagnosis of TB infection varies considerably from
as early as 21 days to as late as 3 years post-transplant. Also, M.
tuberculosis infections in recipients of UCBT may have a rapidly
progressive course and present with bacteremia or disseminated
infection (16, 26, 41). Infections caused by M. tuberculosis have
been reported in patients receiving autologous HSCT and the
incidence varies from 0.0 to 0.23% (5, 19, 32, 42). Old literature
suggested that the risk of M. tuberculosis infections in recipients of
autologous HSCT was similar to that in the general population and
that no obvious risk factors were associated with the development
of TB infections in autograft recipients (19, 29). However, over
the last decade, M. tuberculosis infections have been increasingly
reported in recipients of autologous HSCT (43, 44). Also, such
infections have been reported as early as day 30 post-autologous
HSCT and M. tuberculosis infections in these patients have been
reported to coexist with other infections such as cytomegalovirus
infection and adenovirus-related hemorrhagic cystitis. M. tuber-
culosis infections in autograft recipients may present with pul-
monary involvement as well as extra-pulmonary manifestations
such as bone marrow involvement with pancytopenia and myeloid
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maturation arrest (43, 44). The recent use of monoclonal antibod-
ies, such as rituximab, to control the primary underlying disease
could have contributed to the recent increase in the incidence of M.
tuberculosis infections in recipients of autologous HSCT (43, 44).
DIAGNOSIS OFM. TUBERCULOSIS INFECTIONS IN RECIPIENTS OF
HSCT
The diagnosis of M. tuberculosis infections in HSCT recipients
should be based on: clinical grounds, sputum microscopy and
cultures, cultures of pleural and pericardial fluid in addition to
bronchoalveolar lavage (BAL) samples, bone marrow cultures,
serology, molecular testing, and tissue biopsies (1, 40). Tissue biop-
sies from liver, spleen, lungs, lymph nodes, and bone marrow may
show caseating or non-caseating granulomas (1, 40). The histol-
ogy may be atypical showing either granuloma in the absence of
caseation necrosis or lack of granuloma in the presence of caseous
necrosis. The latter can be explained by impaired T-cell function
in the early post-HSCT phase (1, 16, 26). Unfortunately, a defin-
itive diagnosis of M. tuberculosis infections in HSCT recipients is
usually difficult to be established because: immunological defecits
may lead to mild and non-specific clinical manifestations and his-
tology does not usually show typical granuloma formation (1, 16,
26). Therefore, a high index of suspicion should be maintained in
recipients of HSCT living in endemic areas and presenting with:
unexplained fever, cough, pleuritic chest pain, diffuse reticulon-
odular shadows on chest X-ray, rapidly progressive illness, and
disseminated infection (1, 12, 20, 32, 37, 40).
TREATMENT OFM. TUBERCULOSIS INFECTIONS IN HSCT
RECIPIENTS
Provided there is no evidence of drug resistant strains of M.
tuberculosis, the recommended treatment schedule for adults
with M. tuberculosis infections includes: (1) an induction phase
for 2 months composed of the standard first-line anti-TB
agents: rifampicin: 600 mg/day, INH: 300 mg/day, pyrazinamide
1600 mg/day, and ethambutol 1200 mg/day, and (2) a maintenance
phase for 7–10 months with rifampicin 600 mg/day and INH
400 mg/day (21). Multidrug-resistant TB (MDR-TB) has been
reported in recipients of allogeneic HSCT. MDR-TB is more fre-
quent in SOT recipients than in HSCT patients (45). The potential
risk of MDR-TB may act as a major obstacle to effective treatment
of M. tuberculosis infections following HSCT despite appropri-
ate anti-TB medications (46). Early introduction of second-line
anti-TB chemotherapy may have a good outcome (45).
CHEMOPROPHYLAXIS IN RECIPIENTS OF HSCT
Isoniazid prophylaxis has been successfully used to prevent reac-
tivation of old TB infections in recipients of HSCT. However,
routine prophylaxis against TB infections in patients with skin test
reactivity and a normal chest X-ray should be balanced against
the possibility of drug-induced hepatotoxicity in recipients of
HSCT (1, 18, 23, 29, 35, 37, 42, 47). Therefore, INH prophylaxis
should not be given routinely, but close follow-up and moni-
toring for reactivation of latent infections is recommended. In
geographical locations where TB is prevalent: pre-and post-HSCT
follow-up for TB should be taken into consideration, and the use
of INH prophylaxis should be seriously considered (1, 18, 23,
29, 35, 37, 42, 47).
Indications for INH prophylaxis in candidates and recipients of
HSCT include: (1) exposure to an individual with active, infectious
(sputum-smear positive) pulmonary, or laryngeal TB regardless
the TST or interferon-Gamma release assay (IGRA), (2) Having a
positive TST results, regardless of prior bacillus Calmettte-Guerin
(BCG) vaccination without previous treatment and no evidence
of active TB disease, and (3) having a positive IGRA result, with-
out previous anti-TB therapy and no evidence of active TB disease
(11, 15, 35). Exposure of a candidate or a recipient of HSCT to
an active, but non-infectious, patient with extra-pulmonary TB
does not require preventive therapy. The value of INH prophy-
laxis in recipients of HSCT living in countries with high prevalence
of TB should be considered at institutional or regional levels. In
countries with high prevalence of MDR-TB, single-agent prophy-
laxis may be ineffective (11, 15, 35). In recipients of HSCT living
in countries that are endemic for TB, INH prophylaxis has been
shown to be effective in preventing TB in these immunocompro-
mised hosts (5, 28, 48). It is recommended that INH should be
administered for at least 6–9 months and that it should be com-
menced prior to or immediately after completion of conditioning
therapy for HSCT (11, 28, 48). INH prophylaxis is well tolerated
post-HSCT even with concurrent administration of fluconazole.
However, concurrent use of INH with itraconazole is not recom-
mended. The impact of using voriconazole or posaconazole on
INH prophylaxis is still unknown (11).
Other prophylactic regimens include rifampicin for 4 months
although its use is associated with substantial drug interac-
tions with immunosuppressive agents and other medications.
Rifampicin and pyrazinamide combination is not recommended
because of significant hepatotoxicity that can be caused by this
drug combination (11). BCG vaccination is contraindicated in
recipients of HSCT due to the risk of having disseminated BCG
infection. Donors who live or originate from countries that are
endemic for TB have a risk of active TB infection or LTBI similar
to the rest of the population. These donors need to be assessed
thoroughly and active TB should be ruled out in them prior to
donation of HSCs (11).
COURSE AND PROGNOSIS OFM. TUBERCULOSIS INFECTIONS IN HSCT
RECIPIENTS
In recipients of HSCT having M. tuberculosis infections, high
mortality rates are encountered in patients with miliary TB and
disseminated TB infections (1, 16, 19, 21, 33, 36). Mortality rates
are higher in allogeneic HSCT than in autologous HSCT recipi-
ents. Mortality rates due to M. tuberculosis infections in recipients
of HSCT range from 0.0 to 75% and mortality is related to the
type of HSCT, the degree of immunosuppression, and depends on
how early the diagnosis of M. tuberculosis infection is made (1, 16,
19, 21, 33, 36).
Usually, M. tuberculosis infections in recipients of HSCT are
localized to a certain organ such as lungs or central nervous system
(1, 16, 30, 31). Occasionally, the infection is disseminated and the
course may be rapidly progressive and the following complications
may be encountered: disseminated infection, severe hyperpyrexia,
adult respiratory distress syndrome, hypotension, hypoxia, sepsis,
multi-organ failure, and death. However, early diagnosis, prompt
initiation of appropriate anti-TB chemotherapy and having a
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localized infection as well as a drug-sensitive strain carry good
outcome (1, 16, 30, 31).
NEW INSIGHTS IN THE PATHOGENESIS, DIAGNOSIS, AND
MANAGEMENT OF TB
RECENT FINDINGS IN THE IMMUNOPATHOGENESIS OF TB
GRANULOMAS
The immunology of TB is complex and multifaceted. Identifying
the immune mechanisms that lead to control of initial infection
and prevent reactivation of LTBI is crucial to combat TB (49). One
of the main features of the immune response to M. tuberculosis
is the formation of granulomas (50). Understanding granulo-
mas requires an analysis of the complex interplay of innate and
adaptive molecular signals that control the focal accumulation of
inflammatory cells and activity of their cellular components (51).
Granulomas consist of macrophages that produce cytokines such
as interferon-γ, highly differentiated cells such as multinucleated
giant cells, epithelial cells, and foamy cells, surrounded by a rim
of lymphocytes that include CD4 T-cells (50, 52, 53). Despite that
granulomas act to constrain the infection, some bacilli can actu-
ally survive inside them in a dormant state for a long time (50,
52–54). Although granuloma formation seems to be primarily a
host defense mechanism for containing bacteria, it also shelters
bacteria by providing them with a niche in which they can per-
sist in a latent form until an opportunity arises for reactivation
and spread. Also, evolution of drug resistance develops during the
latency phase (50, 52–54).
For unclear reasons, acid fast bacilli (AFB) will reactivate in
10% of the latently infected individuals, escape the granuloma and
spread throughout the body, thus giving rise to clinical disease,
and are finally disseminated throughout the environment (50).
Studies in mice have shown that production of pro-inflammatory
cytokines, growth factors, and leukocyte surface markers by gran-
uloma cells indicates continued processes of activation and deac-
tivation of granuloma inflammatory cells during the progress of
LTBI (52).
Understanding the pathophysiology of granulomas is critical
for the design of new vaccines and anti-TB drugs. Chemokine
receptor analysis of granulomas has revealed an age-dependent
heterogeneity of immunological responses, thus chemokines may
become potential targets for therapeutic interventions (50–52, 55).
It is unrealistic to call TB granuloma as an unsuccessful host
defense as it successfully contains the infectious focus in more
than 90% of cases. The 10% of individuals who progress to active
TB suffer from disturbances in the balance between inflammatory
reaction to the infectious agent and immunological defenses of
the host (54). Granulomas are protective for dormant AFB, but are
capable of having tissue destructive nature by behaving as a tumor
rather than an active site of bacterial control (55–57). Granulo-
mas are highly dynamic and are shaped by the pathogen and the
immune response elements of the host. To secure transmission to
a new host, M. tuberculosis has evolved to drive T-cell immunity to
the point that necrotizing granulomas leak into the bronchial cav-
ities to facilitate expectoration of AFBs. Complete eradication of
AFB in granulomas does not occur since M. tuberculosis is able to
persist within the granuloma, reactivate, and escape under certain
circumstances (57).
ROLE OF MESENCHYMAL STEM CELLS IN THE PATHOGENESIS OF TB
Despite the generation of robust host immune responses, M.
tuberculosis can successfully evade host immunity to establish
a persistent infection by incompletely understood mechanisms.
M. tuberculosis suppresses T-lymphocyte responses by recruiting
mesenchymal stem cells (MSCs) into the site of infection (58).
Recruitment of MSCs to the periphery of granulomas plays a
crucial role in the pathogenesis of M. tuberculosis infection by
confining the organism within the granulomas on one hand and
keeping M-TB-specific T-cells at the bay on the other hand (58).
Thus, large numbers of MSCs infiltrate into the site of TB infec-
tion and position themselves between the harbored pathogen
and effector T-cells that target the pathogen. MSCs suppress T-
lymphocyte responses by producing nitrous oxide. Therefore,
targeting MSCs or nitrous oxide seems a feasible therapeutic inter-
vention for designing new effective therapeutic and preventive
strategies against TB (58–60).
M. tuberculosis may maintain long-term intracellular viabil-
ity in a human bone marrow-derived CD271+/CD45-(BM-MSC)
population in vitro. Also, M. tuberculosis resides in an equiv-
alent population of BM-MSCs in a mouse model of dormant
TB infection (61). Viable M. tuberculosis has been detected in
CD271+/CD45− BM-MSCs isolated from individuals who had
successfully completed months of anti-TB drug therapy. Thus,
CD271+ BM-MSCS may provide a long-term protective intra-
cellular niche in the host in which dormant M. tuberculosis can
reside. M. tuberculosis can persist in hostile intra-cellular microen-
vironments evading immune cells and drug treatment. Finally, BM
cellular niche may be important for the maintenance of the non-
replicating phase of the M. tuberculosis life cycle (61). Glycation of
the functional domain of CD271+MSCs, which have been proven
to be the protective niche for M. tuberculosis, occurs in patients
with uncontrolled DM and can modulate the genesis of LTBIs in
chronic DM (62).
NEW DIAGNOSTIC TOOLS FOR TUBERCULOSIS
The most common direct method for diagnosing TB worldwide
is sputum-smear microscopy, which was developed more than
100 years ago, where bacteria are observed in sputum samples
examined under a microscope (63). Acid resistance is one of the
main features of mycobacteria that allows for quick identification.
Consequently, sputum culture remains the gold standard for the
diagnosis of pulmonary TB (63). Liquid media are considered the
standard method for the isolation and culture of M. tuberculo-
sis as they have a better quality of isolation compared to solid
media. The introduction of liquid culture-based techniques was a
great improvement for diagnosis, shortening the time to detection
to 10–14 days instead of several weeks needed for conventional
media (63).
Molecular detection of M. tuberculosis continues to change the
landscape of TB diagnosis. Because of the slow growth rate of
M. tuberculosis, conventional methods for its detection based on
solid culture media take several weeks to yield results (63). With
the purpose of obtaining faster results and earlier diagnosis of
M. tuberculosis infection, several molecular methods have been
introduced and evaluated in numerous studies. These molecular
tests are summarized in Table 4 (63–68). M. tuberculosis-specific
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Table 4 | It shows new diagnostic tests forM. tuberculosis.
Category Type of test/technology used Examples
Immunodiagnostics (1) γ interferon release assays; IGRAs for
diagnosis of latent TB infection
- Quantiferon-TB gold in-tube (QFT-GIT)
- T-SPOT.TB assay
(2) Tuberculosis biomarkers (1) Neutrophil percentage in bronchoalveolar lavage
(2) Serum prolactin level
(3) C-reactive protein
(4) Combined interferon-γ inducible protein-10 and
interferon-γ
(5) Combination of 6 serum micro-RNAs:
- hsa-miR-378, - hsa-miR-29c
- hsa-miR483, - hsa-miR-101
- hsa-miR-22, - hsa-miR-320b
Molecular tests used for detection of M.
tuberculosis in clinical specimens
(1) Nucleic acid amplification assays
(2) Lateral flow assays
(3) Line probe assays
(4) DNA sequencing techniques
- Accu Probe (Gen-Probe, Inc., San Diego, CA, USA)
- INNO-LiPA Mycobacteria (LiPA, Innogenetics, Ghent,
Belgium)
- Geno Type Mycobacterium assay (Hain Diagnosika,
Germany)
- TB peptide nucleic acid fluorescence in situ hybridization
(Dako, A/S Glostrup, Denmark)
- PCR-restriction fragment length polymorphism analysis
(PRA)
- DNA microarray or high density oligonucleotide arrays
Detection of drug resistance - Molecular techniques are used in testing
drug susceptibility
- Genes involved in drug resistance:
- kat G - rrs
- inh A - rpsL
(1) Line probe assays: PCR-based reverse-hybridization line
probe assay (Inno-LiPA Rif TB test, Innogenetics, NV,
Ghent, Belgium)
(2) Real-time PCR Xpert MTB assay for detection of
rifampicin resistant M. tuberculosis strains
- rpo B - emb B (3) Array-based technologies: multiplex PCR for detection of
genetic mutations involved in drug resistance
New technologies in the pipeline for
detection of M. tuberculosis
(1) LAM-urine antigen detection using ELISA techniques
(2) Use of chromatographic techniques for identification of volatile organic compound as markers in
clinical specimens
(3) Bead-based methods for detection and identification
(4) Simplified smart flow cytometry
(5) Broad nucleic acid amplification-mass spectrometry
M. tuberculosis, Mycobacterium tuberculosis; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay.
nucleic acid amplification tests (NAATs) are the most frequently
used molecular tests for laboratory diagnosis of TB (63). The
NAAT tests provide a reliable way of increasing the specificity of
diagnosis but sensitivity is too poor to rule out disease particularly
in smear-negative disease where clinical diagnosis is equivocal and
where the need is greatest (4). For pleural TB and TB menin-
gitis, adenosine deaminase (ADA) tests have high sensitivity but
limited specificity. NAATs have high specificity to rule in disease
and could be used in conjunction with ADA and interferon-γ to
increase sensitivity for ruling out disease (4).
Critical parameters of newly developed enzyme-linked
immunosorbent assay (ELISA) have been optimized and the cock-
tail antigens have specificity and sensitivity of >98% as compared
to other commercially available diagnostic tests. The newly devel-
oped ELISA that employs a cocktail of secretary proteins of M.
tuberculosis, is an effective tool that can be used for routine
screening and early-stage diagnosis of active TB (69).
Automated liquid culture systems and molecular line probe
assays are recommended by the WHO as the gold standard first-
line DST. The use of this system has not been cleared by the food
and drug administration (FDA) in the USA for DST of second-
line drugs and thus most laboratories rely on agar proportion as
the reference standard (63). With the purpose of detecting drug
resistance in a shorter time, several molecular assays have been
introduced and these are listed in Table 4 (63–68). Studies have
shown that genetic mutations play a significant role in the evo-
lution of drug resistance. Examples of the genes involved in drug
resistance are shown in Table 4 (68). Also, examples of the new
technologies for detection of M. tuberculosis that are in the pipeline
are included in Table 4 (65).
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TUBERCULOSIS BIOMARKERS
Tuberculosis biomarkers have the following potential applications:
(1) classifying patients at a single time point as having active TB,
LTBI, or no disease, (2) predicting future risk of reactivation, (3)
monitoring eradication of LTBI, and (4) predicting end points for
clinical trials by serving as surrogate markers of cure following
anti-TB chemotherapy or vaccination against TB. Unfortunately,
the progress in developing biomarkers for TB infection, in general,
has been slow (70). However, a number of biomarkers have been
shown to be useful in the diagnosis of pulmonary TB in immuno-
compromised individuals and these are shown in Table 4 (71–74).
Several studies testing new biomarkers and utilizing new tech-
nologies such as proteomics, transcriptomics and metabolomics
are underway. Hopefully, these trials will ultimately determine a
panel of biomarkers that can help not only in establishing the
diagnosis but also in the follow-up of TB infections (70).
IGRAs IN THE DIAGNOSIS OF TB
The diagnosis of LTBI is recommended in patients with HM and
in recipients of HSCT. New in vitro T-cell based IGRAs, which
utilize specific M. tuberculosis antigens have been introduced into
routine practice in recent years (75). TST is the most widely used
test for the diagnosis of TB infections and it has been an important
and a traditional way for detecting LTBIs for a long time. How-
ever, the operational and biological limitations of TST indicate
the need for an improved approach to diagnose TB infections. An
accurate diagnosis of TB infection is very essential to prevent the
progress from LTBI to active TB so that the overall burden of TB
disease is diminished. In patients with HM and in recipients of
HSCT, T-SPOT.TB may be a more useful screening test for LTBI
and active TB than TST (75). IGRAs are diagnostic tools for LTBI
and they are not affected by BCG vaccination status. There are two
major IGRAs available: (1) quantiferon-TB gold in-tube (QFT-
GIT) assay and (2) T-SPOT.TB assay (65, 75–77) (Table 4). IGRAs
have sensitivity of more than 95% for diagnosis of LTBI. However,
the sensitivity of T-SPOT.TB appears to be higher than that of
QFT-GIT or TST (76). In the USA, the 2010 centers for disease
control and prevention (CDC) guidelines indicate that IGRAs can
be used in stead of TST in all situations in which the CDC rec-
ommends TST as an aid in diagnosing M. tuberculosis infections.
IGRAs are preferred for patients with history of BCG vaccination
while TST is preferred for testing children under the age of 5 years
(76). The 2013 Canadian TB standards indicate that both TST and
IGRAs are acceptable alternatives for LTBI diagnosis, either test
can be used for LTBI screening in any of the situations in which
testing is indicated with some preferences and exceptions. For ser-
ial testing in populations exposed to TB, data are insufficient for
interpretation of IGRA conversion and reversion (76). Positive
QFT.TB assay results predict development of TB in recipients of
HSCT in whom LTBI cannot be detected by TST (77).
THE ROLE OF RADIOLOGY INM. TUBERCULOSIS INFECTIONS
Pulmonary infections are an important cause of morbidity and
mortality during the course of treatment in patients with HM
and in recipients with HSCT (78). In these immunocompromised
patients: bacterial, viral, fungal, and mycobacterial organisms may
infect the lungs (78). Occasionally, the infectious agents can be
recovered but, at times, cultures are negative and invasive pro-
cedures such as BAL or transbronchial biopsies are required to
determine the etiology of pulmonary infiltrates. Radiological find-
ings may be helpful in predicting the etiology of pulmonary
infection and may also help in prompt initiation of appropriate
antimicrobial therapy (78).
High resolution (HR) CAT scans of chest are the preferred
method for evaluation of a lung infiltrate over plain chest radi-
ography because they are more sensitive in detecting pulmonary
infiltrates earlier and they are more capable of better characteriza-
tion of the infiltrates (79). In patients with HM and in recipients
of HSCT, HR-CAT scans have a high degree of sensitivity (>85%),
a high negative predictive value (>85%) in detecting pneumo-
nia and a gain of 5 days compared to chest X-rays. Consequently,
clinical management is changed based on HR-CAT scan findings
(79). CAT scan appearances in pulmonary TB include: air space
consolidation; pulmonary nodules; interstitial or septal thicken-
ing; cavity formation; tree-in-bud sign; ground glass opacification;
pleural effusions, as well as enlarged and may be necrotic lymph
nodes (78, 80). In patients with febrile neutropenia, HR-CAT scan
of chest is an excellent modality in the diagnostic work-up allowing
early detection and characterization of pulmonary abnormalities.
In pulmonary TB, HR-CAT scans have 90% sensitivity and 97.02%
specificity (80).
THE EMERGING ROLE OF PET SCANS IN TB DIAGNOSIS
CAT scans and magnetic resonance imaging (MRI) provide excel-
lent structural resolution for visualization of areas of infection and
inflammation, but mainly after becoming so advanced to cause
significant anatomical tissue damage (81, 82). Fluorodeoxyglu-
cose positron emission tomography (FDG–PET) scans are highly
sensitive in detecting foci of infection early and they fulfill most of
the criteria established for molecular imaging. In patients with TB
infections, FDG–PET scans can show intense multifocal uptake in
involved areas, such as lymph nodes, bones, and lung parenchyma,
and they determine active foci of infection as well as the extent of
these infections. They are useful in monitoring and follow-up of
complications related to these infections (81, 82).
On PET scans, TB appearances may mimic those of malig-
nancy such as lymphoma or other infections such as invasive
fungal infections (83). C-11 acetate accumulates in tumors but
not in infectious or inflammatory lesions. Therefore, incorpora-
tion of C-11 acetate in PET scanning may help to differentiate TB
from malignancy (83). Although a high standardized uptake value
(SUV) of more than 2.5 is usually attributed to malignancy, SUV
values ranging between 2 and 21 have been described in patients
with tuberculous infections (83).
NEW ANTI-TB THERAPIES
Barriers to improvements in the outcomes of anti-TB therapies
include: (1) long treatment duration resulting in poor patient
adherence to treatment and loss of patients follow-up, (2) complex
therapeutic regimens that involve expensive and toxic medications,
(3) toxic effects and drug interactions particularly if the patient is
receiving other medications such as antiretroviral treatment or
immunosuppressive therapies following transplantation, and (4)
evolution of MDR strains (84). MDR isolates of M. tuberculosis
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arise as a consequence of sequential accumulation of a genetic
mutation conferring resistance to single therapeutic agents (85).
MDR-TB is caused by M. tuberculosis that is resistant to at least
INH and rifampicin, which are the two most effective first-line
anti-TB drugs (84, 86, 87). Extensively drug-resistant TB (XDR-
TB) is MDR-TB with additional resistance to any of the fluoro-
quinolones and to at least one of three injectable anti-TB agents
such as amikacin, kanamycin, and capreomycin (84, 86, 87).
After 50 years of no new anti-TB drug development, a promis-
ing pipeline is emerging through the repurposing of old drugs,
re-engineering of existing antibacterial compounds, and discov-
ery of new and novel therapies that are active against dormant
as well as persistent populations of M. tuberculosis (84). New
drugs and chemical compounds have been tried with success in
the treatment of infections caused by M. tuberculosis and these are
included in Table 5 (84, 88, 89). New drugs and new combina-
tion regimens in clinical trials are expected to increase therapeutic
efficacy and shorten treatment duration in both drug-susceptible
and drug-resistant strains of M. tuberculosis (84, 88, 89). Stud-
ies in non-human primate models of active TB and LBTI have
shown that targeting mycobacteria in hypoxemic environments by
administration of drugs such as metronidazole may not only pre-
vent reactivation of LTBI but may shorten the treatment duration
of active TB as well (90).
The use of immunotherapy as an adjunct to anti-TB
chemotherapy may improve success rates for treatment of
Table 5 | It shows new therapeutics active againstM. tuberculosis.
Type of therapy Examples
(1) New antimicrobials active
against M. tuberculosis
• New fluoroquinolones and
fluoroquinolone containing compounds
- Levofloxacin - OFLOTUB
- Moxifloxacin - NIRT
- Rifaquine - REMoxTB
• Linezolid, • Rifapentine
• Clofazimine, • Bedaquiline and
delamanid
(2) Chemical agents active
against M. tuberculosis
• Sutezolid, • OPC-67683
• AZD 5847, • SQ-109
• PA-824, • BTZ-043
•TMC-207, • PNU-100480
(3) Adjunctive
immunotherapy
• IL-2, • IL-24
• IL-7, • Interferon-γ
(4) Autologous mesenchymal
stem cell transplantation
• In conjunction with anti-tuberculous
chemotherapy
• Effective against MDRTB and XDRTB
strains
(5) Targeted M. tuberculosis
therapy
• Animal studies have shown that
metronidazole targets M. tuberculosis
in hypoxemic environment
M. tuberculosis, Mycobacterium tuberculosis; IL, interleukin.
MDRTB, multidrug-resistant tuberculosis; XDRTB, extensively drug resistant
tuberculosis.
MDR-TB, shorten the time for drug-sensitive TB, and improve the
immunity of individual by enhancing TB elimination to prevent
disease recurrence. The adjunctive immunotherapies are listed in
Table 5 (91).
ROLE OF AUTOLOGOUS HSCT IN THE TREATMENT OFM.
TUBERCULOSIS INFECTIONS
Recently, autologous HSCT has successfully been used in the treat-
ment of MDR-TB and even XDR-TB (Table 5) (92, 93). In one
study, 27 patients, in whom previous long-term treatment with
anti-TB drugs alone had been ineffective, were included (15 with
MDR-TB and 12 with XDR-TB). All patients received autolo-
gous MSCs. Positive clinical responses were obtained in all 27
patients, bacterial discharge from lungs stopped in 20 patients
after 3–4 months, and resolution of tissue damage and lung cav-
itation was obtained in 11 patients (92). In the 16 patients who
had follow-up for 18–24 months: persistent remission of tubercu-
lous process was achieved in nine patients and significant positive
bacteriological and morphological responses were obtained in six
patients. So, inclusion of transplantation of autologous MSCs into
the course of anti-TB treatment may be a promising maneuver to
enhance the efficacy of treatment in patients with drug-resistant
pulmonary TB (92).
In another phase 1 clinical trial, 30 patients with microbiolog-
ically confirmed MDR-TB or XDR-TB were included (93). After
4 weeks of anti-TB drug therapy autologous HSCT was performed.
Autologous bone marrow-derived MSCs were infused and the dose
of MSCs was 1× 106 cells/kg body weight. The adverse events
encountered were mostly grade I or II (93). Therefore, in patients
with drug resistant TB, autologous MSCs can be used in com-
bination with standard anti-TB chemotherapy. However, adjunct
therapy using MSCs needs to be evaluated in controlled phase 2
trials to assess effects on immune responses and clinical as well
as microbiological outcomes of this newly evolving therapeutic
modality (93).
VACCINATION AGAINSTM. TUBERCULOSIS INFECTIONS
The BCG vaccine was developed as an attenuated live vaccine for
TB control almost a century ago. Despite being the most widely
used vaccine in human history, it has two major limitations: its
poor efficacy against adult pulmonary TB and its disconcerting
safety in immunocompromised hosts (94–96). During the past
5 years, an alarming increase in the number of patients with MDR-
TB and XDR-TB has been noted, particularly in East Europe, Asia,
and South Africa. Treatment outcomes, with the available thera-
peutic regimens for DR-TB, are usually poor (97). Although sub-
stantial progress in drug development for TB has been achieved,
scientific progress toward development of interventions for pre-
vention and improvement of drug treatment outcomes have lagged
behind. So, innovative interventions and novel adjunct treatments
are needed to combat the growing pandemic of MDR-TB and
XDR-TB by improving its cure rates (97).
A novel, safe, widely applicable and more effective vaccine
against TB is desperately sought to achieve disease control. Over
the last 20 years, tremendous progress has been achieved in TB
vaccine research and development from a pipeline virtually empty
of new TB candidate vaccines in the early 1990s to an era in which
almost 20 vaccine candidates are present at different stages in the
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clinical trial pipeline (97, 98). The potential TB vaccines are either
subunit vaccines aimed at boosting BCG-prime vaccination or
recombinant BCG constructs that may replace BCG vaccine in the
future (95, 96). Additional vaccine candidates will enter clinical
trials in the near future including post exposure vaccines for indi-
viduals with LTBI. Ultimately, vaccines that prevent or eradicate
M. tuberculosis infection would be the best possible option (95).
The next 10–15 years will be critical for TB vaccines to demonstrate
protective efficacy and safely. Next generation vaccines should be
designed with the aim of preventing infection or achieving ster-
ile eradication perhaps by redirecting immune responses at M.
tuberculosis antigens expressed during latency or by using new
platforms (98).
Having a strategy of host-directed therapies focused on the
immune response of anti-TB treatment could be particularly
beneficial for patients with MDR-TB or XDR-TB. Hence, more
attention should be given to host-directed preventive and thera-
peutic interventions (97). Improved knowledge of immunology,
molecular microbiology, cell biology, and biotechnology has paved
the way toward effective and safe vaccines against TB. The pipeline
of new vaccine candidates from preclinical to clinical testing could
be accelerated by development of biomarkers that can predict the
clinical outcome of TB (95). As there is no clear regulatory pathway
for TB vaccines, global sharing of information among regulatory
authorities from countries engaged in development of TB vaccines
is required (99).
CONCLUSION
M. tuberculosis infections carry significant morbidity and mortal-
ity in recipients of various forms of HSCT particularly in patients
living in endemic geographic locations. These infections have a
number of risk factors and they cause a wide spectrum of clini-
cal manifestations and complications. A high index of suspicion
should be maintained in HSCT recipients presenting with compat-
ible clinical or radiological features. Prompt diagnosis and early
institution of appropriate therapy are associated with favorable
outcome.
The plethora of new diagnostic techniques will hopefully help
clinicians, radiologists, and laboratory staff to have early diagno-
sis. The newly evolving therapeutics, cellular therapies as well as
vaccines will ultimately be translated into more optimal manage-
ment of these potentially life-threatening infections in this peculiar
group of immunocompromised patients.
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